Funded by the Bone Cancer Research Trust

2008 - Click on the titles for a description of the research

Professor Susan Burchill, St James’s University Hospital, Leeds (£49,591)
Investigating the combination of fenretinide and TRAIL receptor agonists in ESFT.

Dr Anke Jozefien Roelofs and Professor Michael John Rodgers, University of Aberdeen (£29,942)
The role of tumour-associated macrophages in the anti-osteosarcoma effects of bisphosphonates.

Dr Rachael Windsor, University College Hospital, London (£49,956)
A pilot pharmacogenomic study of the influenence of cytotoxic metabolising gene polymorphisms on toxicity and outcome in resectable osteosarcoma.
This project has continued following an application for further funding in April 2008.

Dr Agamemnon Grigoriadis, King’s College, London (£29,720)
Targeting FGF receptor signaling for the treatment of osteosarcoma.

Professor Jillian Birch, University of Manchester (£47,555)
A pilot Study of the aetiology and genetics of bone tumours in children, teenagers and young adults.

Professor Nicholas Athanasou and Dr Helen Knowles, University of Oxford (£27,213)
Effect of hypoxia on growth, apoptosis and angiogenic capacity of osteosarcoma and Ewing’s Sarcoma cells: regulation by Hypoxia-inducible Factor.

Professor Josef Vormoor, Northern Institute for Cancer Research, Newcastle University (£31,772)
Molecular mechanisms of organ-specific Ewing’s sarcoma metastasis.

Dr Richard McNally, Newcastle University (£30,601)
Environmental contributions to the aetiology of bone tumours in young people: small area analyses.

---

2007 - Click on the titles for a description of the research

Professor Adrienne Flanagan, Royal National Orthopaedic Hospital, Middlesex (£28,800)
Cancer stem cells in Osteosarcoma: potential for development of new prognostic markers and treatment.

Dr Agamemnon Grigoriadis, King’s College, London (£29,720)
Identifying a novel role for deregulated Fibroblast Growth Factor Receptor signalling in the growth control of human Osteosarcoma cells.

Dr Rachael Windsor, University College Hospital, London (£30,000)
A pilot pharmacogenomic study of the influence of cytotoxic metabolising gene polymorphisms on toxicity and outcome in resectable Osteosarcoma.

26 & 27th March 2007, Belfry Hotel, West Midlands
International Consensus Meeting on Local Control of Ewing’s Sarcoma.

---

2006 - Click on the titles for a description of the research

Dr Richard McNally, Newcastle University (£29,985)
An epidemiological study of bone tumours in children and young adults.

Dr John Anderson, Unit of Molecular Haematology and Cancer Biology,
Institute of Child Health, London (£34,500)
Development of clinical protocols for Ewing’s Sarcoma treatment using gene transfer of T cell receptors.

Funded by the Adam Dealey Foundation

Fifth Round 2005 in conjunction with Patricia Smith

6) Dr Sue Burchill, University of Leeds (£24,516) - "Exploiting hypoxia and angiogenesis for therapeutic advantage in Ewing's Sarcoma family of tumours"

7) Dr Jeremy Whelan University College London Hospitals (£25,0000) - "Two clinical trials of treosulfan in relapsed and advanced Ewing's Sarcoma"

Fourth Round 2004

5) Dr Ian Lewis St James's University Hospital Leeds (£25,000) - "Developing a methodology to investigate international differences in presentation and outcome in patients with Ewing's Sarcoma"

Third Round 2002

4) Prof Chris Boshoff/ Dr Richard Frow The Wolfson Institute (£20,000) "RNA interference as a novel therapeutic tool against Ewing's Sarcoma/Primitive Neuroectodermal Tumours"

Second Round 2000

3) Dr Sue Burchill, University of Leeds (£33,377) - "The role of novel FGFr3 variant in the development an behaviour of Ewing's Sarcoma"

First Round 1998

1) Dr Sue Burchill, University of Leeds (£20,992) - "Basic fibroblast growth factor (bFGF)-induced apoptosis and fibroblast growth factor receptor (FGFr) expression in Ewing's Sarcoma"

2) Dr Nick Coleman, University of Cambridge (£10,000) - "Assessment of chromosomal abnormalities I Ewing's / PNET tumours by 24 colour FISH, colour banding and comparative genomic hybridisation"